← Leaderboards
Richard F. Ambinder
Johns Hopkins University
$9,273,650
Attributed
$14,075,167
Total exposure
18
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,662,796 · 20
By mechanism
P50$14,340,574 · 3
R01$8,354,252 · 3
P01$4,040,357 · 4
U01$2,890,348 · 3
R21$737,247 · 2
P30$285,768 · 1
Top collaborators
- Rena Xian15 shared
- Martin G Pomper5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Rena Xian$3,698,061
- Richard Bruce Roden$11,133,737
- William George Nelson$34,555,726
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsLymphomaHodgkin DiseaseClinical TrialsTumorBiopsyDiagnosisHuman Herpesvirus 4InvestigationPlasmaCostResourcesHuman SubjectCellsTranslatingProgramsMolecularLeadCause Of DeathOrganDiagnosticLaboratoriesEnsureChemotherapy
Grant awards (65)
Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva$667,061
U01 · FY2025 · CA · contact PI
Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma$265,305
U01 · FY2025 · CA · contact PI
Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma$65,268
U01 · FY2025 · CA · contact PI
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$848,142
R01 · FY2024 · CA · contact PI
Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva$673,198
U01 · FY2024 · CA · contact PI
Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma$357,595
U01 · FY2024 · CA · contact PI
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$849,329
R01 · FY2023 · CA · contact PI
Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva$713,651
U01 · FY2023 · CA · contact PI
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$104,391
R01 · FY2023 · CA · contact PI
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$814,364
R01 · FY2022 · CA · contact PI
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$104,391
R01 · FY2022 · CA · contact PI
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$816,273
R01 · FY2021 · CA · contact PI
Clonal Immunoglobulin DNA and Lymphoma Diagnosis$141,985
R21 · FY2021 · CA · contact PI
Hematologic Malignancies and BMT Program - 02$55,387
P30 · FY2021 · CA · contact PI
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$800,059
R01 · FY2020 · CA · contact PI
Clonal Immunoglobulin DNA and Lymphoma Diagnosis$175,110
R21 · FY2020 · CA · contact PI
Hematologic Malignancies and BMT Program - 02$55,387
P30 · FY2020 · CA · contact PI
Hematologic Malignancies and BMT Program - 02$55,387
P30 · FY2019 · CA · contact PI
Hematologic Malignancies and BMT Program - 02$55,373
P30 · FY2018 · CA · contact PI
Hematologic Malignancies and BMT Program - 02$6,864
P30 · FY2018 · CA · contact PI
Hematologic Malignancies and BMT Program - 02$2,068
P30 · FY2018 · CA · contact PI
Hematologic Malignancies and BMT Program - 02$55,302
P30 · FY2017 · CA · contact PI
Molecular Imaging in the Treatment of Kaposi's Sarcoma$196,770
P50 · FY2015 · CA · contact PI
Plasma and serum biomarkers for Hodgkin lymphoma$178,438
R21 · FY2015 · CA · contact PI
BETR Therapy for Herpesvirus-Associated Tumors$520,698
R01 · FY2014 · CA
Plasma and serum biomarkers for Hodgkin lymphoma$241,714
R21 · FY2014 · CA · contact PI
Molecular Imaging in the Treatment of Kaposi's Sarcoma$190,903
P50 · FY2014 · CA · contact PI
Molecular Imaging in the Treatment of Kaposi's Sarcoma$191,503
P50 · FY2013 · CA · contact PI
BETR Therapy for Herpesvirus-Associated Tumors$1
R01 · FY2013 · CA
BETR Therapy for Herpesvirus-Associated Tumors$550,261
R01 · FY2012 · CA
Molecular Imaging in the Treatment of Kaposi's Sarcoma$177,940
P50 · FY2012 · CA · contact PI
BETR Therapy for Herpesvirus-Associated Tumors$553,505
R01 · FY2011 · CA
BETR Therapy for Herpesvirus-Associated Tumors$582,447
R01 · FY2010 · CA
SPORE in Lymphoma$304,005
P50 · FY2009 · CA · contact PI
SPORE in Lymphoma$1,150,000
P50 · FY2007 · CA · contact PI
VACCINATION OF PATIENTS AT RISK FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER$938
M01 · FY2007 · RR · contact PI
SPORE in Lymphoma$2,485,217
P50 · FY2006 · CA · contact PI
Adult Hodgkin's Disease and Epstein Barr Virus$355,239
R01 · FY2006 · CA · contact PI
Network Laboratory$148,270
U01 · FY2006 · CA · contact PI
VACCINATION OF PATIENTS AT RISK FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER$4,795
M01 · FY2006 · RR · contact PI
SPORE in Lymphoma$2,545,025
P50 · FY2005 · CA
Adult Hodgkin's Disease and Epstein Barr Virus$363,788
R01 · FY2005 · CA
VACCINATION OF PATIENTS AT RISK FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER$6,480
M01 · FY2005 · RR
SPORE in Lymphoma$2,534,934
P50 · FY2004 · CA
Adult Hodgkin's Disease and Epstein Barr Virus$363,788
R01 · FY2004 · CA
Vaccination of Patients at Risk for Post-Transplant Lymphoproliferative Disorder$2,037
M01 · FY2004 · RR
SPORE in Lymphoma$2,482,109
P50 · FY2003 · CA
HERPESVIRUS-ASSOCIATED MALIGNANCIES IN HIV PATIENTS$829,337
P01 · FY2003 · CA
Adult Hodgkin's Disease and Epstein Barr Virus$363,788
R01 · FY2003 · CA
SPORE in Lymphoma$2,082,168
P50 · FY2002 · CA
HERPESVIRUS-ASSOCIATED MALIGNANCIES IN HIV PATIENTS$807,762
P01 · FY2002 · CA
Adult Hodgkin's Disease and Epstein Barr Virus$363,788
R01 · FY2002 · CA
EBV RELATED TUMORS$225,914
P01 · FY2002 · CA
EBV and Hodgkins disease$0
P50 · FY2002 · CA
TRIAL OF EBV SPECIFIC CYTOTOXIC T LYMPHOCYTES WITH EBV ASSOCIATED MALIGNANCIES$0
M01 · FY2002 · RR
HERPESVIRUS-ASSOCIATED MALIGNANCIES IN HIV PATIENTS$786,718
P01 · FY2001 · CA
EBV RELATED TUMORS$225,914
P01 · FY2001 · CA
TRIAL OF EBV SPECIFIC CYTOTOXIC T LYMPHOCYTES WITH EBV ASSOCIATED MALIGNANCIES$0
M01 · FY2001 · RR
CORE--PATHOLOGY/SEROLOGY$0
P01 · FY2001 · CA
IMMUNE CONTROL OF EPISTEIN BARR VIRUS IN HODGKINS DISEASE$0
P01 · FY2001 · CA
HERPESVIRUS-ASSOCIATED MALIGNANCIES IN HIV PATIENTS$580,354
P01 · FY2000 · CA
EBV AND POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS$225,914
P01 · FY2000 · CA
CORE--PATHOLOGY/SEROLOGY$179,222
P01 · FY2000 · CA
IMMUNE CONTROL OF EPISTEIN BARR VIRUS IN HODGKINS DISEASE$179,222
P01 · FY2000 · CA
TRIAL OF EBV SPECIFIC CYTOTOXIC T LYMPHOCYTES WITH EBV ASSOCIATED MALIGNANCIES$0
M01 · FY2000 · RR